USPTO Reinstates Sanofi Antibody Patent Rejections in Precedential Double-Patenting Ruling

USPTO Reinstates Sanofi Antibody Patent Rejections in Precedential Double-Patenting Ruling

The U.S. Patent and Trademark Office issued a precedential decision on August 6, 2026, reaffirming six obviousness-type double patenting rejections in Ex parte Baurin, a case involving Sanofi antibody claims.[1][2] The panel said the anti-harassment rationale can independently justify a rejection, and it outlined a framework meant to make double-patenting review more predictable for applicants and examiners.[1][2]

This ruling matters beyond the United States because it affects global biotech patent strategy, especially for multinational pharmaceutical companies managing overlapping portfolios across major markets.[1][2] It also signals a stricter approach to patent term management and claim sequencing in high-value therapeutic inventions.[1][2]